CN1852706A - 血清素再摄取抑制剂和阿戈美拉汀的联合用药 - Google Patents

血清素再摄取抑制剂和阿戈美拉汀的联合用药 Download PDF

Info

Publication number
CN1852706A
CN1852706A CNA2004800191380A CN200480019138A CN1852706A CN 1852706 A CN1852706 A CN 1852706A CN A2004800191380 A CNA2004800191380 A CN A2004800191380A CN 200480019138 A CN200480019138 A CN 200480019138A CN 1852706 A CN1852706 A CN 1852706A
Authority
CN
China
Prior art keywords
serotonin reuptake
reuptake inhibitor
pharmaceutical composition
serotonin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800191380A
Other languages
English (en)
Chinese (zh)
Inventor
S·维利格尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33566216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1852706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1852706A publication Critical patent/CN1852706A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800191380A 2003-07-04 2004-06-29 血清素再摄取抑制剂和阿戈美拉汀的联合用药 Pending CN1852706A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301031 2003-07-04
DKPA200301031 2003-07-04
US48547903P 2003-07-07 2003-07-07

Publications (1)

Publication Number Publication Date
CN1852706A true CN1852706A (zh) 2006-10-25

Family

ID=33566216

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800191380A Pending CN1852706A (zh) 2003-07-04 2004-06-29 血清素再摄取抑制剂和阿戈美拉汀的联合用药

Country Status (17)

Country Link
US (3) US20060205754A1 (enExample)
EP (1) EP1643985B1 (enExample)
JP (1) JP2007513052A (enExample)
KR (1) KR20060032598A (enExample)
CN (1) CN1852706A (enExample)
AR (1) AR047553A1 (enExample)
AT (1) ATE499096T1 (enExample)
AU (1) AU2004253225A1 (enExample)
BR (1) BRPI0411665A (enExample)
CA (1) CA2530880A1 (enExample)
DE (1) DE602004031527D1 (enExample)
DK (1) DK1643985T3 (enExample)
IL (1) IL172965A0 (enExample)
IS (1) IS8154A (enExample)
MX (1) MXPA06000018A (enExample)
NO (1) NO20060242L (enExample)
WO (1) WO2005002562A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781437A (zh) * 2010-02-11 2012-11-14 瑟维尔实验室 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
WO2008035177A2 (en) * 2006-09-18 2008-03-27 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
US20080280991A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
PL2517700T3 (pl) * 2011-04-28 2013-12-31 Zentiva Ks Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
WO2013013060A1 (en) * 2011-07-19 2013-01-24 Lycus, Llc Agomelatine derivatives
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
WO2014024896A1 (ja) * 2012-08-08 2014-02-13 株式会社メドレックス アゴメラチンを含有する貼付剤組成物
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US6617891B2 (en) * 2001-09-26 2003-09-09 Intel Corporation Slew rate at buffers by isolating predriver from driver
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781437A (zh) * 2010-02-11 2012-11-14 瑟维尔实验室 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
CN102781437B (zh) * 2010-02-11 2014-07-30 瑟维尔实验室 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Also Published As

Publication number Publication date
AU2004253225A1 (en) 2005-01-13
IL172965A0 (en) 2006-06-11
MXPA06000018A (es) 2006-03-21
EP1643985A1 (en) 2006-04-12
EP1643985B1 (en) 2011-02-23
BRPI0411665A (pt) 2006-08-08
WO2005002562A1 (en) 2005-01-13
ATE499096T1 (de) 2011-03-15
KR20060032598A (ko) 2006-04-17
US20130217776A1 (en) 2013-08-22
DK1643985T3 (da) 2011-06-06
CA2530880A1 (en) 2005-01-13
JP2007513052A (ja) 2007-05-24
DE602004031527D1 (de) 2011-04-07
US20100267772A1 (en) 2010-10-21
NO20060242L (no) 2006-01-17
US20060205754A1 (en) 2006-09-14
AR047553A1 (es) 2006-01-25
IS8154A (is) 2005-11-28

Similar Documents

Publication Publication Date Title
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
US20020103249A1 (en) Combination of a serotonin reuptake inhibitor and irindalone
CN1889938A (zh) 用于预防或减少自杀性和治疗与自杀性相关的重性抑郁症的美金刚
WO2004112786A2 (en) Gaboxadol for treating depression and other affective disorders
CN100430063C (zh) 使用5-羟色胺再摄取抑制剂的联合药物
US20050234093A1 (en) Treatment of depression and other affective disorders
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
AU2014342520A1 (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
CN1845730A (zh) 5－羟色胺再摄取抑制剂与克塞平的组合
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
HK1096872A (en) The combination of a serotonin reuptake inhibitors and agomelatine
MXPA06002504A (es) Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
KR20060124639A (ko) 세로토닌 재흡수 억제제 및 히스타민 ３ 수용체안타고니스트, 역 아고니스트 또는 부분 아고니스트의 조합
CN1809350A (zh) 抑郁症和其他情感障碍的治疗
CN1845744A (zh) 5－羟色胺再摄取抑制剂和阿莫沙平的联合
ES2361507T3 (es) La combinación de un inhibidor de reabsorción de la serotonina y agomelatina.
MXPA06002279A (es) Combinacion de un inhibidor de la reabsorcion de serotonina y amoxapina.
JP2023520899A (ja) 頭痛障害の処置のための方法
CN101358379A (zh) 使用5-羟色胺再摄取抑制剂的联合疗法
CN101472575A (zh) 5-htp组合疗法
HK1082681A (en) Combination therapy wherein a serotonin reuptake inhibitor is used

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096872

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1096872

Country of ref document: HK